

Response to comments on: Efficacy of dorzolamide in improving ocular blood flow in patients with open-angle glaucoma: The Indian carbonic anhydrase inhibitor trial

Dear Editor,

This is regarding the comments on “Efficacy of dorzolamide in improving ocular blood flow in patients with open-angle glaucoma: The Indian carbonic anhydrase inhibitor trial.” Thank you for your comments^[1] and interest in reading our article.^[2]

The study was a single-blinded one where in the glaucoma consultant knew about the patient but the radiologist who performed Doppler was not aware of the diagnosis and the treatment history of the patient.^[3] Moreover, the radiologist was in another center so he was not having access to the case records and we did take Doppler imaging for healthy volunteers too during the study period.

Yes, it is a good suggestion. Literature has enough evidence to prove that dorzolamide eye drops increase the ocular blood flow when compared with timolol^[4] and latanoprost.^[5] But in our study, we had studied the efficacy of only dorzolamide as it was a pilot study to see the effect in Indian eyes as there was no publication regarding this aspect from our country at the time of initiation of this study.

Color Doppler imaging (CDI) measurements were taken using GE healthcare produces these Ultrasound machines with a 7.5 MHz linear probe in the same center with a single qualified examiner.

The values are highly interpreter-dependent so it would be better to do any follow-up with the same examiner. The values

do change with the pressure exerted during an examination, so we made sure that all scans were done by an experienced radiologist.

We understand the importance of retinal nerve fiber analysis and follow-up in our study but we were not able to get those data due to logistic issues.

We once again appreciate your input. As researchers and constant learners, it is encouraging to know that our article has reached many ophthalmologists.

Financial support and sponsorship

Research Grant from Cipla.

Conflicts of interest

There are no conflicts of interest.

Murali Ariga, Pratheeba Devi Nivean¹

Chairman, Swamy Eye Hospital, ¹Medical Director, MN Eye Hospital, Chennai, Tamil Nadu, India

Correspondence to: Dr. Pratheeba Devi Nivean, MN Eye Hospital, Chennai, Tamil Nadu, India. E-mail: devi.nivean@gmail.com

References

1. Srikanth K, Khurana DA. Comments on: Efficacy of dorzolamide in improving ocular blood flow in patients with open-angle glaucoma: The Indian carbonic anhydrase inhibitor trial. *Indian J Ophthalmol* 2023;71:2312-3.
2. Nivean, PD, Ariga M, Chithra MR, Gohil P, Das S, Jaideep G. Efficacy of dorzolamide in improving ocular blood flow in patients with open-angle glaucoma: The Indian carbonic anhydrase inhibitor trial. *Indian J Ophthalmol* 2022;70:4164-7.
3. David S, Khandhar PB. Double-Blind Study. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK546641/>. [Updated 2022 Jul 18].
4. Fuchsjäger-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjashchna J, *et al*. Effect of dorzolamide and timolol on ocular

blood flow in patients with primary open angle glaucoma and ocular hypertension. *Br J Ophthalmol* 2005;89:1293-7.

5. Zeitz O, Matthiessen ET, Reuss J, Wiermann A, Wagenfeld L, Galambos P, *et al*. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: A randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. *BMC Ophthalmol* 2005;5:6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website: https://journals.lww.com/ijo
	DOI: 10.4103/IJO.IJO_71_23

Cite this article as: Ariga M, Nivean PD. Response to comments on: Efficacy of dorzolamide in improving ocular blood flow in patients with open-angle glaucoma: The Indian carbonic anhydrase inhibitor trial. *Indian J Ophthalmol* 2023;71:2313-4.

© 2023 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow